What Avenacy does

Avenacy is a U.S. specialty pharmaceutical company founded in October 2023 and headquartered in Schaumburg, Illinois, focused on commercializing FDA-approved generic sterile injectable medications for acute care hospitals, outpatient clinics, physician offices, and — more recently — mail order and retail pharmacy channels. The company operates an asset-light model, sourcing its 28 launched products (as of June 2026) from a global network of nearly 20 cGMP-certified development and manufacturing partners across five key geographies. Its portfolio spans oncology (Melphalan, Fulvestrant, Zoledronic Acid), cardiovascular and anticoagulation (Bivalirudin, Eptifibatide), antiemetics (Fosaprepitant, Palonosetron, Metoclopramide), a foundational antibiotic portfolio (Ampicillin, Penicillin G, Piperacillin-Tazobactam, Nafcillin, Doxycycline, Ampicillin-Sulbactam), anesthetics (Propofol, Lidocaine), and other critical care injectables (Furosemide, Magnesium Sulfate, Tranexamic Acid, Dexmedetomidine, Diphenhydramine, Bortezomib).

Avenacy differentiates through proprietary highly-visible label designs intended to reduce administration errors and improper doses, as well as ready-to-use formulations such as Magnesium Sulfate premix IV bags and Tranexamic Acid in 0.7% Sodium Chloride. Products are distributed primarily through U.S. wholesale distribution partners, with the company building a regional field sales team of Regional Business Development Managers to develop direct relationships with hospital and alternate care purchasers. Management is led by CEO and co-founder Jeff Yordon (formerly of Sagent Pharmaceuticals and Athenex Pharmaceutical Division), co-founder Kam Phulwani, and co-founder and board member Dr. Patrick Soon-Shiong (NantCapital).

The company generates revenue through unit sales of generic injectable pharmaceuticals at undisclosed pricing, with individual product U.S. market sizes ranging from approximately $8 million to $71 million annually. Avenacy has reported FY2025 year-over-year revenue growth of 212% and gross profit expansion of 335%, with over 3 million units sold since January 2024 and a 25-product milestone achieved by year-end 2025. It has raised capital through a NantCapital investment (August 2024), an approximately $26 million equity round (November 2024), and an Asset Based Lending facility with Texas Capital Bank (June 2025), supporting plans to launch 14 or more additional products in 2026 and continued channel expansion.

Name

Avenacy

Legal name

Avenacy, Inc.

Website

https://avenacy.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Avenacy is a U.S. specialty pharmaceutical company founded in 2023 that commercializes FDA-approved generic sterile injectable medications across oncology, antibiotics, cardiovascular, and critical care through a network of cGMP manufacturing partners, selling to hospitals, clinics, and pharmacies via wholesale distribution and a growing field sales team.

Ownership category

akta.pro rank

Product category

Generic Injectable Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Sterile Injectable Generics (HLAIABAC)

Keywords

• Generic injectable pharmaceuticals
• Sterile injectable medications
• Specialty pharmaceutical manufacturing
• Critical care injectables
• Generic drug distribution

Headquarters

HQ city

Schaumburg

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D

Revenue model

1. Generic Injectable Pharmaceuticals Sales: Avenacy generates revenue through the sale of FDA-approved generic injectable medications to healthcare facilities including hospitals, outpatient clinics, and physician offices. Products are distributed through wholesale partners. Each product launch represents a potential revenue stream from unit sales, with market sizes for individual products ranging from approximately $8 million to $71 million annually in the U.S.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Avenacy is a specialty pharmaceutical company that develops, manufactures, and distributes FDA-approved generic injectable medications for U.S. healthcare facilities. Its portfolio of 28 launched sterile injectable products spans oncology, antibiotics, antiemetics, cardiovascular, and anesthesia therapeutic areas. Avenacy differentiates through proprietary highly visible packaging/labeling and ready-to-use formulations designed to reduce administration errors, leveraging a global network of nearly 20 cGMP-certified development and manufacturing partners.

Product overview

Avenacy is a specialty pharmaceutical company offering a portfolio of sterile injectable generic medications for U.S. healthcare facilities. The product portfolio consists of FDA-approved generic equivalents of branded injectable drugs spanning multiple therapeutic areas including oncology (Melphalan, Fulvestrant, Zoledronic Acid), cardiovascular/anticoagulation (Bivalirudin, Eptifibatide), antiemetics (Fosaprepitant, Palonosetron, Metoclopramide), antibiotics (Ampicillin, Penicillin G, Piperacillin/Tazobactam, Nafcillin, Doxycycline), anesthetics (Lidocaine, Propofol), and other critical care medications (Furosemide, Magnesium Sulfate, Tranexamic Acid, Dexmedetomidine). The portfolio includes both standard vials and ready-to-use formulations. The company differentiates through unique packaging and labeling designed to reduce medication errors. The products are distributed to acute care hospitals, outpatient clinics, and physician offices through wholesale partners.

Differentiator

Problem solved

Functional benefit

Products and services

• Melphalan for Injection Generic equivalent of Alkeran; 50 mg lyophilized powder kit for palliative treatment of multiple myeloma, supplied to hospitals and oncology treatment centers.
• Bivalirudin for Injection Generic equivalent of Angiomax; 250 mg lyophilized powder single-dose vial anticoagulant used during percutaneous coronary intervention (PCI) and for heparin-induced thrombocytopenia.
• Fosaprepitant for Injection Generic equivalent of Emend; 150 mg single-dose vial antiemetic for chemotherapy-induced nausea and vomiting in oncology settings.
• Fulvestrant Injection Generic equivalent of Faslodex; 250 mg per 5 mL prefilled syringe for HR-positive, HER2-negative advanced breast cancer.
• Furosemide for Injection, USP Generic equivalent of Lasix; 100 mg per 10 mL loop diuretic for edema associated with congestive heart failure, cirrhosis, and renal disease.
• Desmopressin Acetate for Injection, USP Generic equivalent of DDAVP; 4 mcg/mL single-dose and 40 mcg/10 mL multi-dose vials for central diabetes insipidus, hemophilia A, and von Willebrand's disease.
• Eptifibatide Injection Generic equivalent of Integrilin; 75 mg per 100 mL antiplatelet for acute coronary syndrome and PCI procedures.
• Magnesium Sulfate in Water for Injection Ready-to-Use Premix IV bags of magnesium sulfate in 2g/50mL, 4g/100mL, and 4g/50mL concentrations for seizure prevention in preeclampsia/eclampsia and other obstetric and critical care uses.
• Isoproterenol Hydrochloride Injection, USP Generic equivalent of ISUPREL; 0.2 mg/mL and 1 mg/5 mL presentations for heart block, cardiac arrest, bronchospasm during anesthesia, and shock states.
• Tranexamic Acid Injection, USP Generic equivalent of Cyklokapron; 1000 mg per 10 mL antifibrinolytic for reducing hemorrhage in hemophilia patients during tooth extraction and related bleeding indications.
• Prochlorperazine Edisylate Injection, USP Generic equivalent of COMPAZINE; 10 mg per 2 mL multi-dose vial phenothiazine for controlling severe nausea/vomiting and schizophrenia.
• Palonosetron Hydrochloride Injection, USP Generic equivalent of Aloxi; 5-HT3 antagonist antiemetic for chemotherapy-induced and postoperative nausea and vomiting.
• Metoclopramide Injection, USP Generic equivalent of Reglan; 10 mg per 2 mL for diabetic gastroparesis, chemotherapy-induced nausea, postoperative nausea, small bowel intubation, and radiological examination.
• Dexmedetomidine Injection, USP Generic equivalent of Precedex; 200 mcg per 2 mL single-dose vial sedative for ICU and procedural sedation.
• Zoledronic Acid Injection Generic equivalent of Zometa; 4 mg per 5 mL single-dose vial bisphosphonate for bone metastases and hypercalcemia of malignancy.
• Ampicillin for Injection, USP Ampicillin broad-spectrum penicillin antibiotic in 10 g pharmacy bulk package for treating susceptible bacterial infections in hospital settings.
• Ampicillin and Sulbactam for Injection, USP Ampicillin-sulbactam combination antibiotic in 1.5 g, 3 g single-dose vials and 15 g pharmacy bulk package for treating bacterial infections.
• Nafcillin for Injection, USP Nafcillin penicillinase-resistant penicillin antibiotic in 10 g pharmacy bulk package for treating staphylococcal infections.
• Penicillin G Potassium for Injection, USP Penicillin G Potassium antibiotic in 5,000,000 and 20,000,000 unit glass vials for treating susceptible bacterial infections.
• Piperacillin and Tazobactam for Injection, USP Piperacillin-tazobactam combination antibiotic in 3.375 g, 4.5 g single-dose vials and 40.5 g pharmacy bulk package for treating bacterial infections.
• Propofol Injectable Emulsion, USP Generic equivalent of Diprivan; 200 mg/20 mL, 500 mg/50 mL, and 1,000 mg/100 mL single-dose vials for sedation and anesthesia.
• Lidocaine HCl Injection, USP Generic equivalent of XYLOCAINE; 1% lidocaine in 20 mg/2 mL, 50 mg/5 mL, 300 mg/30 mL, and 500 mg/50 mL presentations for local or regional anesthesia.
• Leuprolide Acetate Injection 14 mg per 2.8 mL multi-dose vial kit for hormonal therapy, with channel expansion into mail order and retail pharmacy.
• Dehydrated Alcohol Injection, USP Generic equivalent of Ablysinol; 5 mL ≥99% ethyl alcohol single-dose vials for therapeutic neurolysis.
• Diphenhydramine Hydrochloride Injection, USP Generic equivalent of BENADRYL; 50 mg per mL single-dose vial antihistamine for treating allergic reactions, motion sickness, and parkinsonism.
• Tranexamic Acid in 0.7% Sodium Chloride Injection Ready-to-use tranexamic acid in 0.7% sodium chloride, 1000 mg per 100 mL, for reducing or preventing hemorrhage in hemophilia patients during tooth extraction.

Quantifiable outcome

• Over 3 million units sold since January 2024
• +2 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Four partnerships are on record, tiered major and core.

• Milla Pharmaceuticals Inc. (A.forall)majorTechnology or Integration · 1 May 2024Milla Pharmaceuticals, the U.S. subsidiary of A.forall, partnered with Avenacy to manufacture and distribute Magnesium Sulfate in Water for Injection. Milla Pharmaceuticals is part of Avenacy's global network of development and contract manufacturing partners that have undergone successful FDA inspections based on cGMP standards.
• Qilu Pharmaceutical, Ltd.coreTechnology or IntegrationFDA-approved cGMP-certified contract manufacturing organization. Part of Avenacy's global network of development and manufacturing partners. Manufactured Melphalan Hydrochloride for Injection.
• Arthur GroupcoreTechnology or IntegrationListed as the Abbreviated New Drug Application (ANDA) holder for some products including Melphalan Hydrochloride. Part of Avenacy's development and manufacturing partner network.
• Global Development and Manufacturing Partner NetworkcoreTechnology or IntegrationAvenacy has nearly 20 development and manufacturing partners across five key geographies. These partners have undergone successful FDA inspections based on cGMP standards and form the foundation of the company's supply chain resiliency strategy.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Hospira (Pfizer CentreOne / Pfizer Injectables): Hospira, now part of Pfizer, is the historical U.S. market leader in generic injectable pharmaceuticals. Its broad portfolio across essentially every therapeutic category Avenacy addresses makes it the principal broad incumbent competitor in U.S. hospital injectable supply.
• Sandoz (Novartis): Sandoz is one of the world's largest generics manufacturers with a meaningful sterile injectables portfolio and global manufacturing footprint. While not specialty-focused, it competes directly with Avenacy in many of the same generic injectable SKUs in U.S. hospitals.
• B. Braun Medical: B. Braun is a global medical products and injectable pharmaceutical company with strong U.S. hospital relationships, particularly in IV solutions and anesthesia-related injectables that overlap with Avenacy's Propofol and Lidocaine franchises. It is a relevant broad incumbent competitor.
• Baxter International: Baxter is a large, diversified medical products manufacturer with a significant injectable and infusion pharmaceuticals portfolio competing for the same hospital purchasing decisions as Avenacy. Its broad portfolio and global scale make it a relevant broad incumbent comparable.
• Teva Pharmaceutical Industries: Teva is a global generics leader with a broad sterile injectables portfolio serving U.S. hospitals and clinics. Although much larger and broader than Avenacy, it is a relevant incumbent comparable for pricing, supply continuity, and formulary dynamics in the U.S. injectable generics market.

Direct peers

• Fresenius Kabi: Fresenius Kabi is one of the largest global manufacturers of generic sterile injectable pharmaceuticals, including products directly overlapping Avenacy's portfolio (e.g., Melphalan via the APP legacy). It is the same buyer (hospitals) via the same wholesale channels, making it a primary direct competitor.
• Sagent Pharmaceuticals: Sagent is a specialty injectable generics company also founded by Avenacy CEO Jeff Yordon, and is therefore the closest comparable in portfolio strategy, customer base (hospitals and alternate care), and commercial model. Avenacy explicitly mirrors Sagent's playbook, and Sagent's prior acquisition by Nichi-Iko provides a relevant valuation reference.
• Amphastar Pharmaceuticals: Amphastar is a U.S.-based specialty injectable generics company with a portfolio that overlaps substantially with Avenacy's (e.g., critical care injectables, propofol-adjacent products). It serves the same hospital and alternate care customers through similar wholesale channels, making it a strong direct comparable.
• Athenex Pharmaceutical Division: Athenex's pharmaceutical division, where CEO Jeff Yordon previously served as President, was a specialty injectable business launching 50+ products with strong U.S. hospital sales growth. It is a near-identical strategic template to Avenacy and a direct historical comparable.
• Hikma Pharmaceuticals: Hikma is a leading global generic injectable manufacturer with a substantial U.S. hospital-focused sterile injectables franchise (including the former West-Ward and Bedford assets). It competes head-to-head with Avenacy in the same ANDA-based generic injectables sold through U.S. wholesalers to hospitals.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/avenacy

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avenacy